Acute Lymphoblastic Leukemia Treatment Market Outlook
Acute lymphoblastic leukemia or acute lymphocytic leukemia is a type of leukemia occurs due to the accumulation and overproduction of cancerous white blood cells known as lymphoblasts in the bone marrow. It may spread to other body organs such as liver, spleen, lymph nodes, and central nervous system among others. It mostly occurs in children and sometimes in children with 2-5 years of age and rarely occurs in old age population. Common signs and symptoms associated with acute lymphoblastic leukemia include fatigue, fever, frequent infections, bruising, weight loss, joint pains, and swollen lymph glands among others. It can be diagnosed by bone marrow test, blood test, ultrasound, MRI, and CT scans among others.
Acute Lymphoblastic Leukemia Treatment Market Growth Analysis
Increase in the incidence of acute lymphoblastic leukemia, rise in the R&D activities for the innovation of novel therapies, growing in healthcare expenditure, and advancement in molecular biology and pharmacology for development of novel drugs are anticipated to fuel the market. In addition, rise in awareness programs and increase in healthcare expenditure are expected propel the growth of the market over the forecast period. However, stringent regulatory policies, high cost of treatment, adverse effects associated with the treatment, and complications with chemotherapy are expected to hinder the growth of the market over the forecast period.
Acute lymphoblastic leukemia treatment market is growing at lucrative rate owing to increase in the prevalence of acute lymphoblastic leukemia prevalence in developing countries due to genetic factors. The rise in R&D activities for the innovation of newer chemotherapy and immunotherapy molecules is anticipated to fuel the market. Moreover, acquisitions and mergers, collaborations, and product launchings are the key strategies followed by the companies for dominating the acute lymphoblastic leukemia treatment industry. For instance, In April 2014, Rare Disease Therapeutics, Inc. received FDA approval for Purixan oral suspension, used in the treatment of acute lymphoblastic leukemia. Moreover, in September 2015, Baxter International Inc. acquired Oncaspar product portfolio from the Sigma-Tau Finanziaria S.p.A. for strengthening its acute lymphoblastic leukemia portfolio.
Acute lymphoblastic leukemia treatment market is segmented on the basis of disease type, treatment type, route of administration, and end users
Based on the disease type, the market is segmented into the following:
- Acute B-lymphoblastic Leukemia
- Acute T-lymphoblastic Leukemia
Based on the treatment type, the market is segmented into the following:
- Colony-stimulating Factors
- Tyrosine Kinase Inhibitors
Based on the route of administration, the market is segmented into the following:
Based on the distribution channel, the market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Geographically, acute lymphoblastic leukemia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has a significant growth which is attributed to increase in the prevalence of acute lymphoblastic leukemia (according to estimation of American Cancer Society about 6,590 new cases and 1,430 deaths are observed in U.S.), rise in R&D for innovation of new drugs, and various drugs approved by FDA are fuelling the market in the region. In Europe, rise in prevalence of acute lymphoblastic leukemia majorly in Russia, Norway, and U.K (according to Cancer Research U.K. 2014, about 758 new cases were observed in U.K.), rise in awareness about the disease treatment, and increase in healthcare expenditure are the factors boosting the market. However, Asia Pacific has a lucrative growth which is attributed to high prevalence of the disease majorly in Australia.
Some of the players in acute lymphoblastic leukemia treatment market are Pfizer, Inc. (U.S.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Genzyme Corporation (U.S.). Talon Therapeutic, Inc. (U.S.), Erytech Pharma (France), Baxter International Inc. (U.S.), Novartis AG (Switzerland), and Rare Disease Therapeutics, Inc. (U.S.) to name a few.
- In August 2017, Pfizer, Inc. has received FDA approval for Besponsa (inotuzumab ozogamycin) used in the treatment of refractory B-cell precursor acute lymphoblastic leukemia.
- In August 2017, Novartis AG received FDA approval for Kymriah suspension for intravenous infusion used in the treatment of refractory B-cell precursor acute lymphoblastic leukemia in patients up to 25 years of age.
- The report provides granular level information about the market size, regional market share, and forecast from 2020-2026
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario